Bayer AG acts today as one of the world market leaders in the pharmaceutical and chemical industry. On the way to the top, the company experienced ups and downs for more than 160 years. A dye manufacturer became a globally operated company.
• From the tar dye too aspirin
• Chemistry, pharmaceutical and agricultural
• between high and low – also in the future
Innovation from the tar dye
The history of Bayer AG began in 1863 when Friedrich Bayer and Johann Friedrich Weskott founded a company for the production of synthetic dyes in Barmen (now a district of Wuppertal). The “Friedr. Bayer et Comp.” Specialized in dyes made of coal cabbage – an area that was then considered high -tech. The company grew rapidly and was converted into a stock corporation in 1881.
Step into the pharmacy
A crucial development step took place in 1888 with the establishment of a pharmaceutical department. Bayer increasingly positioned itself as a manufacturer of remedies – and achieved a worldwide breakthrough in 1899 with the market launch of Aspirin. The drug becomes one of the best -known products of medical history and still shapes the company’s image.
Moving to Leverkusen
Bayer exported all over the world before the First World War and achieved around 80 percent of its sales abroad. The company headquarters were moved to Leverkusen in 1912, where Bayer built a modern factory premises with research institutions. The location remains the headquarters of the group to this day.
Dark years and fresh start after the war
During the National Socialism period, Bayer became part of IG Farben, an association of large chemical companies. After the Second World War, IG Farben was dissolved and Bayer was newly built in 1951 as an independent company. The following decades were characterized by reconstruction and expansion. Bayer invested in new products – such as plastic, agrochemicals and modern medication – and grew into a global company again.
Strategic conversion
In the 1990s and early 2000s, Bayer pursued a strategy of diversification and internationalization. The company bought the Canadian rubber company Polysar and took over the agricultural division of Aventis in 2001. At the same time, the chemical division was split off – the independent company Covestro emerged in 2015, which specialized in high -performance plastics and was brought to the stock exchange.
Monsanto takeover
The most profound step in the recent history of Bavaria is the takeover of the US group Monsanto in 2018. For around $ 63 billion, Bayer took over the controversial agricultural giant, known for the weed shelf Roundup. The aim was to make Bayer the world market leader in agricultural technology. However, massive legal risks go hand in hand with the purchase: in the United States, Bayer has been presented with tens of thousands of lawsuits due to alleged health risks through glyphosate. The group had to make provisions in the billions, the share price collapsed and investors’ trust was sustainably shaken.
Economic pressure
The stress caused by legal disputes, plus the process of patents of important medication such as Xarelto and Eylea, led to economic pressure. In 2023 Bill Anderson took over the chairmanship and announced a comprehensive renovation. The goal was and is to make Bayer more efficient, faster and more competitive. With the new organizational model “Dynamic Shared Ownership”, decision -making processes are to be accelerated, hierarchies are broken down and the administration is streamlined. The group plans to save around two billion euros by 2026. In the course of this there is also a Job cuts planned by several thousand employees – especially in administration and research.
Current structure
Today Bayer sees itself as a pure life science company with the three core areas of pharmaceuticals (prescription medication), consumer health (over-the-counter products) and crop science (agricultural technology). The group is represented in over 80 countries, employs around 93,000 employees and achieved sales of around 13.98 billion euros in the Europe, Middle East and Africa region in 2024, as reported on the company website. With innovation centers in North America, Europe and Asia, Bayer remains strongly active in research and development.
Up and down the future
In addition to challenges, Bayer also results in opportunities in the future – for example through new biotechnological developments that Digitization in agriculture and the growing health market. Whether Bayer can successfully implement his reform course will be crucial for whether the group can build on previous success in the future.
Editor finance.net
By the way: Bayer and other US shares are even tradable at Finance.net Zero until 11 p.m. (without order fees, plus spreads). Open Depot now for free And receive a free stock as a gift.
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Bayer
The lever must be between 2 and 20
Advertising